In the US, cetuximab is indicated for treatment of head and neck cancer and colorectal cancer.<\/p>\n
In the EU, cetuximab is indicated for the treatment of epidermal growth factor receptor (EGFR)-expressing, RAS wild-type metastatic colorectal cancer and for the treatment of squamous cell cancer of the head and neck.<\/p>\n
If cetuximab injection are not yet approved or available in your area, you may request its price in India under a specific brand name through IPN. For assistance and guidance, you can contact us by providing complete details. Our pharmaceutical expert will help you find a suitable and practical solution to your query. To receive comprehensive support, please call us at +91 9891 296 838 (Mr. Tarun) \/ +91 9811 747 774 (Mr. Neeraj).<\/p>\n
cetuximab injection is an epidermal growth factor receptor (EGFR) antagonist indicated for treatment of: Squamous Cell Carcinoma of the Head and Neck (SCCHN) & K-Ras Wild-type, EGFR-expressing Colorectal Cancer (CRC).<\/p>\n
Approval Date: 2004 If you have a prescription from a Registered Medical Practitioner (RMP),\u00a0IPN<\/a> in Delhi can assist you in obtaining access to genuine medication.\u00a0 Our professional will provide you with a step-by-step guide on how to legally and safely import cetuximab injection\u201d based on the information you provide.<\/p>\n
\nProprietary Name: On Request
\nActive Ingredient(s): cetuximab injection
\nDosage Forms And Strengths: Injection: 100 mg\/50 mL (2 mg\/mL) or 200 mg\/100 mL (2 mg\/mL) in a single-dose vial.
\nCompany: Eli Lilly and Company
\nCurrent indications: Squamous Cell Carcinoma of the Head and Neck (SCCHN) & K-Ras Wild-type, EGFR-expressing Colorectal Cancer (CRC).
\nMedicine Approved By: \u2013<\/strong>\u00a0European Medical Agency (EMA), Food and Drug Administration (FDA), Health Canada, Therapeutic Goods Administration (TGA), Medsafe (NZ)
\nSummary of FDA approved use on approval date:<\/strong>\u00a0Click Here<\/a><\/p>\nAccess the best support services globally<\/h4>\n